New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BRCM;GILD;GE;BA;DVAX;CSCO;WPRT;CELG;DKS;CLNE;EXEL;HD;SODA;O;SAND;QCOM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
November 17, 2014
14:25 EDTHDHome Depot technical notes ahead of earnings
Subscribe for More Information
14:21 EDTHDEarnings Preview: Home Depot shares up over 17% since last earnings report
Subscribe for More Information
13:57 EDTQCOMQualcomm volatility flat into analyst meeting
Qualcomm November call option implied volatility is at 22, December and January is at 20, February is at 21; compared to its 26-week average of 21 according to Track Data, suggesting non-directional price movement into a company sponsored analyst meeting on November 19
11:06 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
10:31 EDTGEGE sees China order growth despite slowing economy, WSJ says
Subscribe for More Information
09:36 EDTHD, GILDActive equity options trading
Active equity options trading according to Track Data: AAPL PBR BHI GILD MU HD AMZN TSLA YHOO FB TWTR
08:41 EDTHDHome Depot November volatility elevated into Q3 and outlook
Home Depot November call option implied volatility is at 38, December is at 21, January is at 20; compared to its 26-week average of 18 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on November 18.
07:16 EDTCELGMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
05:12 EDTBABoeing signs agreement with Toray Industries for 777X wing composites
Subscribe for More Information
November 16, 2014
13:12 EDTEXELExelixis announces data from trial of XL888 and vemurafenib
Exelixis announced preliminary results from a phase 1 investigator-sponsored trial, IST, evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90, HSP90, in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma. Safety and efficacy results support the further investigation of 90 mg of XL888 twice weekly, BIW and vemurafenib 960 mg twice daily,BID, in additional studies that would include a third agent. The trial results were presented today by Keiran Smalley, Ph.D., an investigator on the trial and an associate professor at H. Lee Moffitt Cancer Center, Tampa, Florida, in a late-breaking oral presentation session at the Society for Melanoma Research 2014 International Congress, which is taking place November 13-16, in Zurich, Switzerland. Based on these results, as well as findings from coBRIM, the phase 3 pivotal trial of cobimetinib, an Exelixis-discovered MEK inhibitor, and vemurafenib in previously untreated metastatic melanoma patients with a BRAF V600 mutation, the Moffitt Center plans to initiate a phase 1b IST of the triple combination of vemurafenib, cobimetinib, and XL888 in a similar patient population. “The BRAF inhibitor vemurafenib is active in BRAF-mutated malignant melanoma, but development of resistance is common. Preclinical studies led by Keiran Smalley, Ph.D. suggested that most BRAF inhibitor resistance mechanisms involve proteins that are clients of HSP90, and the preclinical evaluation of XL888 showed that it is highly active in vemurafenib-resistant melanoma models,” said Jeffrey Weber, MD, Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at the Moffitt Cancer Center and Research Institute in Tampa, FL. “The current phase 1 data show that both drugs can be given together, and compelling initial response results suggest potential cooperative activity.” “About half of metastatic melanoma patients whose tumors harbor a BRAF V600 mutation respond to vemurafenib, but most of them develop resistance and their tumors begin to regrow,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “Multiple mechanisms drive this resistance, and the team at Moffitt found that many of them involve upregulation of HSP90 client proteins that are sensitive to XL888. We look forward to supporting the Moffitt team as they continue to evaluate XL888 as part of our IST program.”
November 14, 2014
17:07 EDTCELGSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
14:53 EDTGILDCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
12:53 EDTQCOMOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
11:48 EDTGILDStocks with call strike movement; GILD BBY
Subscribe for More Information
10:00 EDTHDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:38 EDTGILD, GEActive equity options trading
Subscribe for More Information
09:34 EDTHDHome Depot downgraded to Hold from Buy at Zelman
08:04 EDTGEGE Capital provides $37.5M credit facility to Specialty's Cafe & Bakery
Subscribe for More Information
08:00 EDTGEHalliburton, Baker deal would face 'intense' DOJ scrutiny, says Jefferies
Subscribe for More Information
07:14 EDTCELGAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use